VolitionRx (VNRX) Q2 2026 Earnings Call: Costs Fall as Nu.Q Pipeline Advances
Source Tradingkey
Key Takeaways
- VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of approximately $0.4 million, broadly unchanged from Q2 2025. First-half revenue rose 112% year over year to $1.4 million.
- Q2 operating expenses fell 32% to $4.6 million from $6.7 million, reflecting the company’s cost-reduction program and a 27% year-over-year reduction in headcount.
- Net loss increased to $7.3 million from $6.3 million, primarily due to approximately $3 million of noncash accounting charges related to the Lind convertible notes.
- The Nu.Q NETs finger-prick lateral flow prototype showed approximately 90% correlation with the CE Mark automated assay in samples from critically ill patients with confirmed sepsis.
- Management is targeting a Nu.Q Lung Cancer reimbursement submission in France during Q3 2026, while emphasizing that reimbursement approval remains uncertain.
- Publication of the Nu.Q Vet feline cancer study is expected to trigger a $5 million contractual milestone payment. The prototype detected 86% of feline lymphomas at 97% specificity.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Revenue | Approx. $0.4 million | Approx. $0.4 million | Broadly flat; higher Nu.Q Vet revenue was offset by lower Nu.Q Discover services revenue |
| First-half revenue | $1.4 million | — | Up 112% year over year |
| Operating expenses | $4.6 million | $6.7 million | Down 32% year over year |
| Operating loss | — | — | Down 34% year over year |
| Net loss | $7.3 million | $6.3 million | Increase mainly reflected approximately $3 million of noncash Lind note charges |
| Operating cash used | $5.2 million | $6.3 million | Lower year over year as cost savings began to take effect |
| Cash and cash equivalents | $2.8 million | $1.1 million at Dec. 31, 2025 | Q2 financing included $1.2 million from the ATM facility and $4.1 million from a public offering |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
SpaceX (SPCX) stock rose 12% on Wednesday to $149.29. That is a 36% gain in five sessions and more than $500 billion in new market value.The trigger was software, not rockets. SpaceXAI, the company’s
Micron (MU) stock is holding near $911 after a 189% price rise in 2026. Yet, Wall Street still sees roughly 70% more upside. And there is good reason behind this optimism. The world is short of the me
Standard Chartered analyst Geoffrey Kendrick says his $100 UNI target for 2030 now looks too low. Six weeks of Robinhood Chain fees changed his math.BeInCrypto checked his numbers against on-chain dat
XRP traded at $1.009 on Thursday. It has been pinned to that dollar line since the Senate skipped its CLARITY Act vote and left for recess.That bill would write XRP’s legal status into federal law. It
The S&P 500 closed at a record high on Thursday, lifted by a flat July producer price report. The reading further eased worries about a Federal Reserve rate hike next month.The benchmark index rose 0.
